Multidrug-resistant tuberculosis: Eight years of surveillance in France

European Respiratory Journal

Volumn 22, Issue 5, 2003, Pages 833-837

  Robert, J ^a   Trystram, D ^a   Truffot Pernot, C ^a   Jarlier, V ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Human immunodeficiency virus; Multidrug resistant; Surveillance; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPARFLOXACIN; STREPTOMYCIN; THIOACETAZONE; THIOAMIDE; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; COMORBIDITY; CONTROLLED STUDY; COOPERATION; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FRANCE; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEALTH STATUS; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RACE DIFFERENCE; SEX DIFFERENCE; SPUTUM SMEAR; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; EMIGRATION AND IMMIGRATION; FEMALE; FRANCE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 0242635873     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00014103     Document Type: Article

References (21)

1. Espinal MA, Laszlo A, Simonsen L, et al. Global trends in drug resistance to antituberculosis drugs. N Engl J Med 2001; 344: 1294-1303.
2. Mitchison DA, Nunn A. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
3. Flament-Saillour M, Robert J, Jarlier V, Grosset J. Outcome of multidrug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med 1999; 166: 587-593.
4. World Health Organization. Global tuberculosis control. WHO Report 2001. www.who.int/gtb/publications/globrep01/index.html. World Health Organization, WHO/CDS/TB/2001.287, 2001. Last updated: July 15, 2003.
5. Beck-Sagué C, Dooley SW, Hutton MD, et al. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. JAMA 1992; 268: 1280-1286.
6. Bouvet E, Casalino E, Mendoza-Sassi G, et al. A nosocomial outbreak of multidrug-resistant Mycobacterium bovis among HIV-infected patients. A case-control study. AIDS 1993; 7: 1453-1460.
7. Fischl MA, Uttamchandani RB, Daikos GL, et al. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992; 117: 177-183.
8. Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis. Epidemiology and clinical outcomes. JAMA 1996; 276: 1229-1235.
9. Comstock GW, Cauthen GM. Epidemiology of tuberculosis. In: Reichmann LB, Hershfield ES, eds. Tuberculosis, a Comprehensive International Approach. New York, Marcel Dekker, 1993; pp. 23-48.
10. Canetti G, Gay P, Le Lirzin M. Trends in the prevalence of primary drug resistance in pulmonary tuberculosis in France from 1962 to 1970: a national survey. Tubercle 1972; 53: 57-83.
11. World Health Organization Geneva/International Union Against Tuberculosis and Lung Disease Paris. Guidelines for surveillance of drug resistance in tuberculosis. Int J Tuberc Lung Dis 1998; 2: 72-89.
12. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
13. Veen J, Raviglione M, Rieder H, et al. Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. Eur Respir J 1998; 12: 505-510.
14. Institut de Veille Santaire/European Commission and the national coordinators for tuberculosis surveillance in the World Health Organization European region. EuroTB. Surveillance of tuberculosis in Europe. Report on tuberculosis case notified in 1999. http://www.eurotb.org. 2001.
15. Burgos M, DeRiemer K, Small P, Hopewell P, Daley C. Relative fitness of drug-resistant and drug-susceptible strains of Mycobacterium tuberculosis in San Francisco. Am J Respir Crit Care Med 2002; 165: A18.
16. Loddenkemper R. The need for antituberculosis drug resistance surveillance in Europe. Eur Respir J 2000; 16: 195-196.
17. Grosset J, Trystram D, de Benoist A-C, et al. Surveillance de la tuberculose à bacilles multirésistants en France en 1995. [Surveillance of multidrug-resistant tuberculosis in France, 1995]. Bull Epid Hebdo 1998; 13: 53-54.
18. Gutierrez MC, Vincent V. Contribution du typage moléculaire à la surveillance de la tuberculose multirésistante en France, 1995-2000. [Contribution of molecular typing to multidrug-resistant tuberculosis in France, 1995-2000]. Bull Epid Hebdo 2002; 10/11: 73-75.
19. Crofton J, Chauley P, Maher D. Guidelines for the Management of Drug-Resistant Tuberculosis. Geneva, World Health Organization, 1997.
20. Robert J, Jarlier V. La tuberculose multirésistante en France. Rev Mal Respir 2002; 19: 21-23.
21. Uffredi ML, Robert J, Truffot-Pernot C, Trystram D, Jarlier V, Grosset J. Multidrug-resistant tuberculosis (MDR-TB): prospective study on effectiveness of individually tailored regimens (DOTS-plus strategy). 30th IUATLD World Conference on Lung Health, 1999, Madrid, Spain. Int J Tuberc Lung Dis 1999; 3: Suppl. 1, S83.